speb/financial-data huggingface dataset:
BBIO income_statement (annual, 2024-12-31) — Interest Expense: 99290000.00
BBIO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 99290000.00
BBIO income_statement (annual, 2024-12-31) — Interest Income: 17249000.00
BBIO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 17249000.00
BBIO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 91342000.00
BBIO cash_flow (quarterly, 2024-12-31) — Interest Paid Supplemental Data: 13106000.00
BBIO balance_sheet (annual, 2024-12-31) — Interest Payable: 11056000.00
BBIO balance_sheet (annual, 2024-12-31) — Inventory: 0.00
BBIO balance_sheet (annual, 2024-12-31) — Invested Capital: 253478000.00
BBIO cash_flow (annual, 2024-12-31) — Investing Cash Flow: 60781000.00
BBIO balance_sheet (annual, 2024-12-31) — Investments And Advances: 143747000.00
BBIO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 314741000.00
BBIO cash_flow (quarterly, 2024-12-31) — Issuance Of Capital Stock: 0.00
BBIO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 450000000.00
BBIO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 4696000.00
BBIO balance_sheet (annual, 2024-12-31) — Long Term Debt: 1721382000.00
BBIO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1726078000.00
BBIO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 450000000.00
BBIO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -473417000.00
BBIO balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 143747000.00
BBIO balance_sheet (annual, 2024-12-31) — Minority Interest: 10292000.00
BBIO income_statement (annual, 2024-12-31) — Minority Interests: 7585000.00
BBIO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -140000.00
BBIO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 307215000.00
BBIO balance_sheet (annual, 2024-12-31) — Net Debt: 1040281000.00
BBIO income_statement (annual, 2024-12-31) — Net Income: -535762000.00
BBIO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -535762000.00
BBIO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -543347000.00
BBIO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -535762000.00
BBIO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -535762000.00
BBIO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -543347000.00
BBIO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -543347000.00
BBIO cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -7975000.00
BBIO income_statement (annual, 2024-12-31) — Net Interest Income: -82041000.00
BBIO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 44147000.00
BBIO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -23417000.00
BBIO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -23417000.00
BBIO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -82041000.00
BBIO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 456501000.00
BBIO balance_sheet (annual, 2024-12-31) — Net PPE: 12778000.00
BBIO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -933000.00
BBIO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -1491830000.00
BBIO balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 496186000.00
BBIO balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 17095000.00
BBIO income_statement (annual, 2024-12-31) — Normalized EBITDA: -572955000.00
BBIO income_statement (annual, 2024-12-31) — Normalized Income: -643301540.00
BBIO cash_flow (annual, 2024-12-31) — Operating Cash Flow: -520726000.00
BBIO cash_flow (annual, 2024-12-31) — Operating Gains Losses: -128684000.00
BBIO income_statement (annual, 2024-12-31) — Operating Income: -577368000.00
BBIO income_statement (annual, 2024-12-31) — Operating Revenue: 221902000.00
BBIO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 190044473.00
BBIO balance_sheet (annual, 2024-12-31) — Other Current Assets: 34869000.00
BBIO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 8000.00
BBIO balance_sheet (quarterly, 2024-12-31) — Other Equity Adjustments: 8000.00
BBIO income_statement (annual, 2024-12-31) — Other Income Expense: 117215000.00
BBIO cash_flow (annual, 2024-12-31) — Other Non Cash Items: 19873000.00
BBIO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 18195000.00
BBIO balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 286000.00
BBIO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 12272000.00
BBIO balance_sheet (annual, 2024-12-31) — Other Properties: 12778000.00
BBIO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 0.00
BBIO balance_sheet (quarterly, 2024-12-31) — Other Short Term Investments: 0.00
BBIO income_statement (annual, 2024-12-31) — Other Special Charges: 26590000.00
BBIO income_statement (quarterly, 2024-12-31) — Other Special Charges: 0.00
BBIO balance_sheet (annual, 2024-12-31) — Payables: 9618000.00
BBIO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 76817000.00
BBIO balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 58329000.00
BBIO balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
BBIO income_statement (annual, 2024-12-31) — Pretax Income: -542194000.00
BBIO cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 8158000.00
BBIO cash_flow (annual, 2024-12-31) — Purchase Of Business: -140000.00
BBIO cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -7975000.00
BBIO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -114082000.00
BBIO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -933000.00
BBIO balance_sheet (annual, 2024-12-31) — Receivables: 4722000.00
BBIO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 3878000.00
BBIO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 6075000.00
BBIO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -473417000.00
BBIO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -7526000.00
BBIO income_statement (annual, 2024-12-31) — Research And Development: 506461000.00
BBIO balance_sheet (annual, 2024-12-31) — Restricted Cash: 126000.00
BBIO balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 126000.00
BBIO income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 15334000.00
BBIO balance_sheet (annual, 2024-12-31) — Retained Earnings: -3096263000.00
BBIO cash_flow (annual, 2024-12-31) — Sale Of Investment: 158229000.00
BBIO income_statement (annual, 2024-12-31) — Selling General And Administration: 288931000.00
BBIO balance_sheet (annual, 2024-12-31) — Share Issued: 196236234.00
BBIO income_statement (annual, 2024-12-31) — Special Income Charges: 136126000.00
BBIO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 95800000.00
BBIO balance_sheet (annual, 2024-12-31) — Stockholders Equity: -1467904000.00
BBIO balance_sheet (annual, 2024-12-31) — Tangible Book Value: -1491830000.00
BBIO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 28586460.00
BBIO income_statement (annual, 2024-12-31) — Tax Provision: 1153000.00
BBIO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
BBIO balance_sheet (annual, 2024-12-31) — Total Assets: 919338000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Capitalization: 253478000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Debt: 1730584000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: -1457612000.00
BBIO income_statement (annual, 2024-12-31) — Total Expenses: 799270000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 2376950000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 198646000.00
BBIO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2222550000.00
BBIO income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -592973000.00
BBIO income_statement (annual, 2024-12-31) — Total Unusual Items: 136126000.00
BBIO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 136126000.00
BBIO balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 6191761.00
BBIO balance_sheet (annual, 2024-12-31) — Treasury Stock: 275000000.00
BBIO cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: -2485000.00
BBIO balance_sheet (annual, 2024-12-31) — Working Capital: 566292000.00
BBIO income_statement (quarterly, 2025-03-31) — +Operating Expense: 217796000.00
BBIO income_statement (quarterly, 2025-03-31) — +Total Revenue: 116633000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 27525000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 115265000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1938369000.00
BBIO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 190145253.00
BBIO income_statement (quarterly, 2025-03-31) — Basic EPS: -0.88
BBIO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 683244000.00
BBIO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -1595000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 10124000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 197000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 540599000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 540599000.00
BBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 60328000.00
BBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -1595000.00
BBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -199235000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 17571000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -20005000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Inventory: -3193000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 1587000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 1475000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -2571000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Payable: 17571000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -2434000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -487000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Receivables: -110543000.00
BBIO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -116166000.00
BBIO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -110543000.00
BBIO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -140502000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Common Stock: 197000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: -1648395000.00
BBIO cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 0.00
BBIO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -50052000.00
BBIO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2639000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 67944000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Assets: 695173000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 5209000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 5209000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 11620000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 11620000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 152105000.00
BBIO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 1284000.00
BBIO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 1284000.00
BBIO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 190145253.00
BBIO income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.88
BBIO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -167422000.00
BBIO cash_flow (quarterly, 2025-03-31) — Dividends Received Cfi: 0.00
BBIO income_statement (quarterly, 2025-03-31) — EBIT: -127467000.00
BBIO income_statement (quarterly, 2025-03-31) — EBITDA: -126183000.00
BBIO income_statement (quarterly, 2025-03-31) — Earnings From Equity Interest: -15556000.00
BBIO cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: 15556000.00
BBIO cash_flow (quarterly, 2025-03-31) — End Cash Position: 542742000.00
BBIO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 60328000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Finished Goods: 2636000.00
BBIO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -200830000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 0.00
BBIO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 27802000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 13864000.00
BBIO income_statement (quarterly, 2025-03-31) — Gross Profit: 113994000.00
BBIO income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: 0.00
BBIO income_statement (quarterly, 2025-03-31) — Interest Expense: 42141000.00
BBIO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 42141000.00
BBIO income_statement (quarterly, 2025-03-31) — Interest Income: 5385000.00
BBIO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 5385000.00
BBIO cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 23271000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Interest Payable: 4253000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Inventory: 3954000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 199729000.00
BBIO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -1595000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 128191000.00
BBIO cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 0.00
BBIO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 575000000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 4915000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1848124000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1853039000.00
BBIO cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 575000000.00
BBIO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -459000000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 128191000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Minority Interest: 9730000.00
BBIO income_statement (quarterly, 2025-03-31) — Minority Interests: 2186000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -50052000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Net Debt: 1307525000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income: -167422000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -167422000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -169608000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -167422000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -167422000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -169608000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -169608000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -1595000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Interest Income: -36756000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 116000000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 116000000.00
BBIO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -36756000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -11378000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Net PPE: 13864000.00
BBIO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: 0.00
BBIO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -1676197000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 514807000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 17508000.00
BBIO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -104458000.00
BBIO income_statement (quarterly, 2025-03-31) — Normalized Income: -145697000.00
BBIO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -199235000.00
BBIO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 36711000.00
BBIO income_statement (quarterly, 2025-03-31) — Operating Income: -103802000.00
BBIO income_statement (quarterly, 2025-03-31) — Operating Revenue: 116633000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 189826023.00
BBIO balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 35355000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 6360000.00
BBIO income_statement (quarterly, 2025-03-31) — Other Income Expense: -29050000.00
BBIO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 26635000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 16608000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 352000.00
BBIO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 8231000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Other Properties: 13864000.00
BBIO income_statement (quarterly, 2025-03-31) — Other Special Charges: 21155000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Payables: 27525000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 95469000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 33447000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
BBIO income_statement (quarterly, 2025-03-31) — Pretax Income: -169608000.00
BBIO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 5758000.00
BBIO cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -1595000.00
BBIO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: 0.00
BBIO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: 0.00
BBIO balance_sheet (quarterly, 2025-03-31) — Raw Materials: 0.00
BBIO balance_sheet (quarterly, 2025-03-31) — Receivables: 115265000.00
BBIO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2639000.00
BBIO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 1284000.00
BBIO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -459000000.00
BBIO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -50052000.00
BBIO income_statement (quarterly, 2025-03-31) — Research And Development: 111431000.00
BBIO income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 570000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -3263685000.00
BBIO cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 0.00
BBIO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 106365000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Share Issued: 197423195.00
BBIO income_statement (quarterly, 2025-03-31) — Special Income Charges: -21725000.00
BBIO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 25882000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: -1648395000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -1676197000.00
BBIO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
BBIO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Assets: 881638000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 199729000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Debt: 1858248000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: -1638665000.00
BBIO income_statement (quarterly, 2025-03-31) — Total Expenses: 220435000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2520303000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 186465000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2368198000.00
BBIO income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -104372000.00
BBIO income_statement (quarterly, 2025-03-31) — Total Unusual Items: -21725000.00
BBIO income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -21725000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 7597172.00
BBIO balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 323276000.00
BBIO cash_flow (quarterly, 2025-03-31) — Unrealized Gain Loss On Investment Securities: -3973000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Work In Process: 1318000.00
BBIO balance_sheet (quarterly, 2025-03-31) — Working Capital: 543068000.00
BBIO income_statement (quarterly, 2025-06-30) — +Operating Expense: 240385000.00
BBIO income_statement (quarterly, 2025-06-30) — +Total Revenue: 110565000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 26134000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 76868000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1980805000.00
BBIO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 190517215.00
BBIO income_statement (quarterly, 2025-06-30) — Basic EPS: -0.95
BBIO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 542742000.00
BBIO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -5094000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 8807000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 198000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 748953000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 756892000.00
BBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 302041000.00
BBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -13002000.00
BBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -80681000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -1055000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: 1391000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Inventory: -13389000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -1761000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: 22017000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -3920000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Payable: -1055000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 336000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -22258000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Receivables: 38397000.00
BBIO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 19422000.00
BBIO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 38397000.00
BBIO cash_flow (quarterly, 2025-06-30) — Changes In Cash: 208358000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Common Stock: 198000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: -1787860000.00
BBIO cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 0.00
BBIO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -1995000.00
BBIO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 3653000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 87899000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Assets: 912277000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 4782000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 4782000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 10540000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 10540000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 175854000.00
BBIO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 1317000.00
BBIO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 1317000.00
BBIO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 190517215.00
BBIO income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.95
BBIO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -181903000.00
BBIO cash_flow (quarterly, 2025-06-30) — Dividends Received Cfi: 0.00
BBIO income_statement (quarterly, 2025-06-30) — EBIT: -144021000.00
BBIO income_statement (quarterly, 2025-06-30) — EBITDA: -142704000.00
BBIO income_statement (quarterly, 2025-06-30) — Earnings From Equity Interest: -20189000.00
BBIO cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: 20189000.00
BBIO cash_flow (quarterly, 2025-06-30) — End Cash Position: 751100000.00
BBIO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 302041000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Finished Goods: 5749000.00
BBIO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -85775000.00
BBIO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Business: 0.00
BBIO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: 6548000.00
BBIO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 7000000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 1000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 29513000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 12293000.00
BBIO income_statement (quarterly, 2025-06-30) — Gross Profit: 106912000.00
BBIO income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 0.00
BBIO balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 2100000.00
BBIO income_statement (quarterly, 2025-06-30) — Interest Expense: 37637000.00
BBIO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 37637000.00
BBIO income_statement (quarterly, 2025-06-30) — Interest Income: 3898000.00
BBIO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 3898000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Interest Payable: 14411000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Inventory: 18277000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 61699000.00
BBIO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -13002000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 108002000.00
BBIO cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 0.00
BBIO cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 300000000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 4025000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 1849559000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 1853584000.00
BBIO cash_flow (quarterly, 2025-06-30) — Long Term Debt Issuance: 300000000.00
BBIO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: 0.00
BBIO balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 108002000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Minority Interest: 9441000.00
BBIO income_statement (quarterly, 2025-06-30) — Minority Interests: 1855000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -1995000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Net Debt: 1100606000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income: -181903000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -181903000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -183758000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -181903000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -181903000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -183758000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -183758000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: -4500000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Interest Income: -33739000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -7908000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 300000000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: 300000000.00
BBIO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -33739000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: -3123000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Net PPE: 12293000.00
BBIO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -594000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -1817373000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 828626000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 14667000.00
BBIO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -148899000.00
BBIO income_statement (quarterly, 2025-06-30) — Normalized Income: -186797050.00
BBIO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -80681000.00
BBIO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 17887000.00
BBIO income_statement (quarterly, 2025-06-30) — Operating Income: -133473000.00
BBIO income_statement (quarterly, 2025-06-30) — Operating Revenue: 110565000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 191162659.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 60240000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 7212000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 1000.00
BBIO income_statement (quarterly, 2025-06-30) — Other Income Expense: -14446000.00
BBIO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 23237000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 18105000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 545000.00
BBIO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -452000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Properties: 12293000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 7939000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Payables: 28234000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 116133000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 37187000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
BBIO income_statement (quarterly, 2025-06-30) — Pretax Income: -181658000.00
BBIO cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 7159000.00
BBIO cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: -4500000.00
BBIO cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -7908000.00
BBIO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -594000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Raw Materials: 11463000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Receivables: 76868000.00
BBIO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 3653000.00
BBIO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 1317000.00
BBIO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: 0.00
BBIO cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -1995000.00
BBIO income_statement (quarterly, 2025-06-30) — Research And Development: 111231000.00
BBIO income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 805000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -3445588000.00
BBIO cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 0.00
BBIO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 129154000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Share Issued: 198759831.00
BBIO income_statement (quarterly, 2025-06-30) — Special Income Charges: -805000.00
BBIO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 37241000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: -1787860000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -1817373000.00
BBIO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 1300950.00
BBIO income_statement (quarterly, 2025-06-30) — Tax Provision: 2100000.00
BBIO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
BBIO balance_sheet (quarterly, 2025-06-30) — Total Assets: 1080190000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 61699000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Debt: 1858366000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: -1778419000.00
BBIO income_statement (quarterly, 2025-06-30) — Total Expenses: 244038000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 2858609000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 167913000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2682755000.00
BBIO income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -134278000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 2100000.00
BBIO income_statement (quarterly, 2025-06-30) — Total Unusual Items: 6195000.00
BBIO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 6195000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 7597172.00
BBIO balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 323276000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Work In Process: 1065000.00
BBIO balance_sheet (quarterly, 2025-06-30) — Working Capital: 736423000.00
BBIO income_statement (quarterly, 2025-09-30) — +Operating Expense: 250495000.00
BBIO income_statement (quarterly, 2025-09-30) — +Total Revenue: 120700000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 18702000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 116518000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 2018335000.00
BBIO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 191854152.00
BBIO income_statement (quarterly, 2025-09-30) — Basic EPS: -0.95
BBIO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 751100000.00
BBIO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -2870000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 8721000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 200000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 642951000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 645942000.00
BBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -894000.00
BBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 4464000.00
BBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -109574000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -7432000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 22173000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Inventory: -6774000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 742000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: 24781000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -2989000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Payable: -7432000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 14741000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 5218000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Receivables: -39650000.00
BBIO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -3931000.00
BBIO cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -39650000.00
BBIO cash_flow (quarterly, 2025-09-30) — Changes In Cash: -106004000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Common Stock: 200000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: -1933070000.00
BBIO cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
BBIO cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -3025000.00
BBIO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 6563000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 118761000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Assets: 839382000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 5294000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 5294000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 9087000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 9087000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 216600000.00
BBIO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 1398000.00
BBIO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 1398000.00
BBIO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 191854152.00
BBIO income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.95
BBIO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -182743000.00
BBIO cash_flow (quarterly, 2025-09-30) — Dividends Received Cfi: 2302000.00
BBIO income_statement (quarterly, 2025-09-30) — EBIT: -138333000.00
BBIO income_statement (quarterly, 2025-09-30) — EBITDA: -136935000.00
BBIO income_statement (quarterly, 2025-09-30) — Earnings From Equity Interest: -15834000.00
BBIO cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: 8065000.00
BBIO cash_flow (quarterly, 2025-09-30) — End Cash Position: 645096000.00
BBIO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -894000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Finished Goods: 4969000.00
BBIO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -112444000.00
BBIO cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: -8760000.00
BBIO cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of Business: 0.00
BBIO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Business: 0.00
BBIO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: 16461000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 2000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 28795000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 12383000.00
BBIO income_statement (quarterly, 2025-09-30) — Gross Profit: 114137000.00
BBIO income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 0.00
BBIO income_statement (quarterly, 2025-09-30) — Interest Expense: 48149000.00
BBIO income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 48149000.00
BBIO income_statement (quarterly, 2025-09-30) — Interest Income: 6239000.00
BBIO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 6239000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Interest Payable: 4253000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Inventories Adjustments Allowances: -1080000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Inventory: 24527000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Invested Capital: -82054000.00
BBIO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 4464000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 92168000.00
BBIO cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
BBIO cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: -300000000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 3427000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 1851016000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 1854443000.00
BBIO cash_flow (quarterly, 2025-09-30) — Long Term Debt Issuance: -300000000.00
BBIO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
BBIO balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 92168000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Minority Interest: 10341000.00
BBIO income_statement (quarterly, 2025-09-30) — Minority Interests: 2194000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: 0.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -3025000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Net Debt: 1208065000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income: -182743000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -182743000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -184937000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -182743000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -182743000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -184937000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -184937000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: -2400000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Interest Income: -41910000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 5032000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -300000000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -300000000.00
BBIO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -41910000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 294111000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Net PPE: 12383000.00
BBIO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -470000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -1961865000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 849257000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 13131000.00
BBIO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -144555000.00
BBIO income_statement (quarterly, 2025-09-30) — Normalized Income: -190299868.44
BBIO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -109574000.00
BBIO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -695000.00
BBIO income_statement (quarterly, 2025-09-30) — Operating Income: -136358000.00
BBIO income_statement (quarterly, 2025-09-30) — Operating Revenue: 120700000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 192633286.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 52395000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 8601000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 2000.00
BBIO income_statement (quarterly, 2025-09-30) — Other Income Expense: -8214000.00
BBIO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 43329000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 25522000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 679000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Properties: 12383000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 2991000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Payables: 18702000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 137463000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 56155000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
BBIO income_statement (quarterly, 2025-09-30) — Pretax Income: -186482000.00
BBIO cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 8020000.00
BBIO cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
BBIO cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -2400000.00
BBIO cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -2968000.00
BBIO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -470000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Raw Materials: 16506000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Receivables: 116518000.00
BBIO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 6563000.00
BBIO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 1398000.00
BBIO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: 0.00
BBIO cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -3025000.00
BBIO income_statement (quarterly, 2025-09-30) — Research And Development: 112874000.00
BBIO income_statement (quarterly, 2025-09-30) — Restructuring And Mergern Acquisition: 8841000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -3628331000.00
BBIO cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 8000000.00
BBIO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 137621000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Share Issued: 200230458.00
BBIO income_statement (quarterly, 2025-09-30) — Special Income Charges: 7620000.00
BBIO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 35262000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: -1933070000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -1961865000.00
BBIO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 63131.56
BBIO income_statement (quarterly, 2025-09-30) — Tax Provision: -1545000.00
BBIO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.01
BBIO balance_sheet (quarterly, 2025-09-30) — Total Assets: 998250000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: -82054000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Debt: 1859737000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: -1922729000.00
BBIO income_statement (quarterly, 2025-09-30) — Total Expenses: 257058000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2920979000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 158868000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2704379000.00
BBIO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -145199000.00
BBIO income_statement (quarterly, 2025-09-30) — Total Unusual Items: 7620000.00
BBIO income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 7620000.00
BBIO balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 7597172.00
BBIO balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 323276000.00